HER2 양성 진행성 또는 전이성 위암 및 식도암 환자에서 화학요법 플러스 또는 마이너스 Tislelizumab 병용 요법에 대한 Zanidatamab 연구 (HERIZON-GEA-01)
HER2 양성 절제 불가능한 국소 진행성 또는 전이성 위식도 선암종(GEA) 대상자에서 Tislelizumab을 포함하거나 포함하지 않는 화학요법과 Zanidatamab을 병용하는 무작위, 다기관, 3상 연구
This study is being done to find out if zanidatamab, when given with chemotherapy plus or minus tislelizumab, is safe and works better than trastuzumab given with chemotherapy.
The patients in this study will have advanced human epidermal growth factor 2 (HER2)-positive stomach and esophageal cancers that are no longer treatable with surgery (unresectable) or chemoradiation, and/or have grown or spread to other parts of the body (metastatic).
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (실제)
등록
단계
단계
- 3단계
확장된 액세스
확장된 액세스
더 이상 사용할 수 없음
- 사용 가능: 현재 이 연구 치료에 대해 확장된 액세스가 가능하며 임상 연구에 참여하지 않은 환자는 약물, 생물학적 제제 또는 의료 기기에 액세스할 수 있습니다. 연구 중입니다.
- 더 이상 사용할 수 없음: 이전에는 이 개입에 대해 확장된 액세스를 사용할 수 있었지만 현재 사용할 수 없으며 앞으로도 사용할 수 없습니다.
- 일시적으로 사용할 수 없음: 현재 이 개입에 대해 확장된 액세스를 사용할 수 없지만 향후 사용할 수 있을 것으로 예상됩니다.
- 마케팅 승인: 개입 대중이 사용할 수 있도록 미국 식품의약국(FDA)의 승인을 받았습니다.
연락처 및 위치
연구 장소
-
-
-
Guatemala City, 과테말라, 01010
- Clinica Medica Especializada CELAN
-
Guatemala City, 과테말라, 01015
- Grupo Medico Angeles
-
Salcajá, 과테말라, 09002
- Centro Medico Integral de Cancerologia CEMIC
-
-
-
-
-
Tbilisi, 그루지야, 0112
- Research Institute of Clinical Medicine
-
Tbilisi, 그루지야, 6000
- High Technology Hospital MedCenter Ltd
-
-
-
-
-
Athens, 그리스, 124 64
- Attikon University General Hospital
-
Thessaloniki, 그리스, 552 36
- Agios Loucas Clinic SA
-
Thessaloniki, 그리스, 54622
- Bioclinic Thessaloniki Oncology Department
-
Thessaloniki, 그리스, 57001
- Interbalkan Medical Center of Thessaloniki Oncology Department
-
-
-
-
-
Pretoria, 남아프리카, 0184
- Wilgers Oncology Centre
-
-
-
-
-
Eindhoven, 네덜란드, 5623 EJ
- Catharina Hospital
-
Leiden, 네덜란드, 2333 ZA
- Leids Universitair Medisch Centrum
-
Tilburg, 네덜란드, 5042 AD
- ETZ-Elisabeth
-
-
-
-
-
Taichung, 대만, 404472
- China Medical University Hospital
-
Taipei, 대만, 11217
- Taipei Veterans General Hospital
-
-
-
-
-
Anyang-si, 대한민국, 14068
- Hallym University Sacred Heart Hospital
-
Busan, 대한민국, 49201
- Dong-A University Hospital
-
Daegu, 대한민국, 41404
- Kyungpook National University Chilgok Hospital
-
Goyang-si, 대한민국, 10408
- National Cancer Center
-
Incheon, 대한민국, 21565
- Gachon University Gil Medical Center
-
Seongnam-si, 대한민국, 13620
- Seoul National University Bundang Hospital
-
Seongnam-si, 대한민국, 13496
- CHA Bundang Medical Center, CHA University
-
Seoul, 대한민국, 03080
- Seoul National University Hospital
-
Seoul, 대한민국, 05505
- Asan Medical Center
-
Seoul, 대한민국, 06351
- Samsung Medical Center
-
Seoul, 대한민국, 03181
- Kangbuk Samsung Hospital
-
Seoul, 대한민국, 02841
- Korea University Anam Hospital
-
Seoul, 대한민국, 08308
- Korea University Guro Hospital
-
Seoul, 대한민국, 03080
- The Catholic University of Korea, Seoul St. Mary's Hospital
-
Seoul, 대한민국, 03686
- Severance Hospital Yonsei University Health System - PPDS
-
Seoul, 대한민국, 06229
- Gangnam Severance Hospital, Yonsei University Health System
-
-
-
-
Hesse
-
Frankfurt am Main, Hesse, 독일, 60488
- Institut für Klinisch-Onkologische Forschung
-
-
-
-
-
Bucharest, 루마니아, 022328
- Fundeni Clinical Institute
-
Cluj-Napoca, 루마니아, 400015
- Prof Dr I Chiricuta Institute of Oncology - PPDS
-
Cluj-Napoca, 루마니아, 400641
- Medisprof SRL
-
Craiova, 루마니아, 200347
- Oncology Center Sfantul Nectarie
-
-
-
-
-
George Town, 말레이시아, 10990
- Hospital Pulau Pinang
-
Kuching, 말레이시아, 93586
- Sarawak General Hospital
-
Putrajaya, 말레이시아, 62675
- National Cancer Institute ( Institut Kanser Negara)
-
-
-
-
-
Mexico City, 멕시코, 03100
- Health Pharma Professional Research S.A de C.V.
-
Monterrey, 멕시코, 64460
- Hospital Universitario Dr. Jose Eleuterio González
-
Oaxaca City, 멕시코, 68020
- Centro de Investigacion Clinica de Oaxaca
-
-
-
-
-
Bonheiden, 벨기에, 2820
- Imelda VZW
-
Brussels, 벨기에, 1200
- Cliniques Universitaires Saint-Luc
-
Ghent, 벨기에, 9000
- UZ Gent
-
Leuven, 벨기에, 3000
- UZ Leuven
-
Liège, 벨기에, 4000
- CHU de Liège
-
-
-
-
-
Barretos, 브라질, 14784-400
- Centro Integrado de Pesquisa - CIP
-
Barretos, 브라질, 14784-400
- Fundação Pio XII Hospital de Câncer de Barretos
-
Belo Horizonte, 브라질, 30130-090
- Cenantron - Centro Avancado de Tratamento Oncologico Ltda
-
Brasília, 브라질, 70840-901
- Centro de Pesquisas Clínicas/Fundação Doutor Amaral Carvalho
-
Fortaleza, 브라질, 60430-230
- Instituto Do Câncer Do Ceará ICC
-
Porto Alegre, 브라질, 90050-170
- Hospital de Clinicas de Porto Alegre (HCPA) - PPDS
-
Porto Alegre, 브라질, 90050-170
- Irmandade Da Santa Casa de Misericordia de Porto Alegre
-
Porto Alegre, 브라질, 91350-200
- Hospital Nossa Senhora Da Conceição
-
Santo André, 브라질, 09060-650
- Núcleo de Pesquisa Clínica da Rede São Camilo
-
Sorocaba, 브라질, 18030-075
- Instituto de Oncologia de Sorocaba
-
São Paulo, 브라질, 01246-000
- Instituto do Cancer do Estado de São Paulo ICESP
-
-
-
-
-
Belgrade, 세르비아, 11070
- Clinical Hospital Center Bezanijska Kosa
-
Belgrade, 세르비아, 11000
- University Clinical Center of Serbia - PPDS
-
Kamenitz, 세르비아, 21204
- Oncology Institute of Vojvodina
-
Niš, 세르비아, 18000
- University Clinical Center Nis
-
-
-
-
-
Badalona, 스페인, 8915
- Hospital Universitario Germans Trias i Pujol
-
Barcelona, 스페인, 08035
- Hospital Universitario Vall d'Hebron - PPDS
-
Girona, 스페인, 17007
- Hospital Universitari de Girona Dr Josep Trueta
-
L'Hospitalet de Llobregat, 스페인, 08908
- Institut Català d'Oncologia (Hospital Duran y Reynals)
-
Madrid, 스페인, 28034
- Hospital Universitario Ramon y Cajal
-
Madrid, 스페인, 28046
- Hospital Universitario La Paz - PPDS
-
Málaga, 스페인, 29010
- Hospital Regional Universitario de Malaga - Hospital General
-
Salamanca, 스페인, 32911
- Complejo Asistencial Universitario de Salamanca - H. Clinico
-
Santander, 스페인, 39008
- Hospital Universitario Marques de Valdecilla
-
Seville, 스페인, 41009
- Hospital Universitario Virgen Macarena
-
Zaragoza, 스페인, 50009
- Hospital Universitario Miguel Servet
-
-
Barcelona
-
Sabadell, Barcelona, 스페인, 08208
- Corporacio Sanitaria Parc Tauli
-
-
Navarre
-
Pamplona, Navarre, 스페인, 31008
- Complejo Hospitalario de Navarra
-
-
-
-
-
Singapore, 싱가포르, 258500
- National Cancer Center Singapore
-
-
-
-
-
Buenos Aires, 아르헨티나, C1181ACH
- Hospital Italiano de Buenos Aires
-
Buenos Aires, 아르헨티나, 1264
- Hospital de Gastroenterología Dr Bonorino Udaondo
-
Buenos Aires, 아르헨티나, C1012
- Instituto de Investigaciones Metabólicas - IDIM
-
Córdoba, 아르헨티나, X5000HXL
- Fundación Centro de Medicina Nuclear y Molecular ER
-
Córdoba, 아르헨티나, X5008HHW
- Centro Médico Privado CEMAIC
-
Pergamino, 아르헨티나, 2700
- Centro de Investigación Pergamino S.A.
-
Viedma, 아르헨티나, R8500ACE
- Centro de Investigación Clínica - Clínica Viedma
-
-
-
-
-
Dublin, 아일랜드, 8
- St James's Hospital
-
-
-
-
-
Tallinn, 에스토니아, 13419
- North Estonia Medical Centre Foundation
-
-
-
-
-
Bristol, 영국, BS2 8ED
- Bristol Haematology and Oncology Centre
-
Edinburgh, 영국, EH4 2XU
- Western General Hospital Edinburgh - PPDS
-
Leeds, 영국, LS9 7TF
- St James University Hospital
-
London, 영국, SE1 9RT
- Guy's and St Thomas' NHS Foundation Trust - Guy's Hospital
-
London, 영국, SW7 3RP
- Royal Marsden Hospital - London
-
London, 영국, SW7 3RP
- Royal Marsden Hospital - Surrey
-
Peterborough, 영국, PE3 9GZ
- Edith Cavell Hospital
-
Sheffield, 영국, S10 2SJ
- Weston Park Cancer Centre
-
-
-
-
-
Dnipropetrovsk, 우크라이나, 49102
- Municipal Non-profit Enterprise "City Clinical Hospital # 4" of Dnipro City Council - PPDS
-
-
-
-
-
Bologna, 이탈리아, 40138
- Azienda Ospedaliero Universitaria Di Bologna - Policlinico S Orsola Malpighi
-
Candiolo, 이탈리아, 10060
- Fondazione del Piemonte per l'Oncologia (IRCCS)
-
Genova, 이탈리아, 16132
- Ospedale Policlinico San Martino
-
Meldola, 이탈리아, 47014
- Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori IRST - PPDS
-
Milan, 이탈리아, 20132
- Ospedale San Raffaele S.r.l. - PPDS
-
Milan, 이탈리아, 20162
- ASST Grande Ospedale Metropolitano Niguarda - Presidio Ospedaliero Ospedale Niguarda
-
Milan, 이탈리아, 20133
- Istituto Nazionale Dei Tumori
-
Modena, 이탈리아, 41124
- Azienda Ospedaliero Universitaria Di Modena Policlinico
-
Reggio Emilia, 이탈리아, 43100
- Arcispedale Santa Maria Nuova
-
Rome, 이탈리아, 00168
- Fondazione Policlinico Universitario A Gemelli
-
Verona, 이탈리아, 37134
- Centro Ricerche Cliniche Di Verona
-
Vicenza, 이탈리아, 36100
- Azienda ULSS 8 "Berica" - Ospedale San Bortolo
-
-
-
-
-
Bhubaneswar, 인도, 751019
- All India Institute of Medical Sciences, Bhubaneswar
-
Gūrgaon, 인도, 122003
- Artemis Hospital
-
Hyderabad, 인도, 500004
- MNJ Institute of Oncology and Regional Cancer Centre
-
New Delhi, 인도, 110076
- Indraprastha Apollo Hospitals
-
Patna, 인도, 800014
- Regional Cancer Centre Indira Gandhi Institute of Medical Sciences
-
Vijayawada, 인도, 520002
- HCG City Cancer Center
-
-
-
-
-
Chūōku, 일본, 104-0045
- National Cancer Center Hospital
-
Fukuoka, 일본, 811-1395
- National Hospital Organization Kyushu Cancer Center
-
Ina, 일본, 362-0806
- Saitama Cancer Center
-
Matsuyama, 일본, 791-0245
- Shikoku Cancer Center
-
Osaka, 일본, 540-0008
- Osaka International Cancer Institute
-
Tokyo, 일본, 135-8550
- The Cancer Institute Hospital of Japanese Foundation For Cancer Research
-
Ōsaka-sayama, 일본, 589-0014
- Kindai University Hospital
-
-
Chiba
-
Chiba, Chiba, 일본, 260-0801
- Chiba Cancer Center
-
Kashiwa-shi, Chiba, 일본, 277-8577
- National Cancer Center Hospital East
-
-
Gihu
-
Gifu, Gihu, 일본, 501-1112
- Gifu University Hospital
-
-
Gunma
-
Ota-shi, Gunma, 일본, 373-8550
- Gunma Prefectural Cancer Center
-
-
Hyôgo
-
Akashi-shi, Hyôgo, 일본, 673-8558
- Hyogo Cancer Center
-
-
Ibaraki
-
Kasama-Shi, Ibaraki, 일본, 309-1793
- Ibaraki Prefectural Central Hospital
-
-
Kagawa-ken
-
Kita-Gun Miki-Cho, Kagawa-ken, 일본, 761-0701
- Kagawa University Hospital
-
-
Kanagawa
-
Yokohama-Shi Asahi-Ku, Kanagawa, 일본, 241-0815
- Kanagawa Cancer Center
-
-
Kumamoto
-
Chuo-Ku, Kumamoto, 일본, 860-8556
- Kumamoto University Hospital - Honjo-Kuhonji Campus A
-
-
Kyoto-shi
-
Sakyo-ku, Kyoto-shi, 일본, 606-8507
- Kyoto University Hospital
-
-
Miyagi
-
Osaki-Shi, Miyagi, 일본, 989-6136
- Osaki Citizen Hospital
-
-
Okayama-ken
-
Kurashiki-Shi, Okayama-ken, 일본, 710-0052
- Kurashiki Central Hospital
-
-
Osaka
-
Suita-Shi, Osaka, 일본, 565-0871
- Osaka University Hospital
-
Takatsuki-Shi, Osaka, 일본, 569-8686
- Osaka Medical and Pharmaceutical University Hospital
-
-
Tokyo
-
Shinjuku-Ku, Tokyo, 일본, 160-8582
- Keio University Hospital
-
-
-
-
-
Beijing, 중국, 100142
- Beijing Cancer Hospital
-
Beijing, 중국, 100191
- Peking University Third Hospital
-
Beijing, 중국, 100021
- Cancer Hospital Chinese Academy of Medical Sciences
-
Beijing, 중국, 101199
- Beijing Luhe Hospital, Capital Medical University
-
Beijing, 중국, 100020
- Beijing Chao-Yang Hospital, Capital Medical University
-
Bengbu, 중국, 233004
- The First Affiliated Hospital of Bengbu Medical College
-
Changsha, 중국, 410031
- Hunan Cancer Hospital
-
Changzhi, 중국, 046099
- Changzhi People's Hospital
-
Changzhou, 중국, 213004
- Changzhou First People's Hospital
-
Chengdu, 중국, 610042
- Sichuan Cancer Hospital & Institute
-
Fuzhou, 중국, 350014
- Fujian Cancer Hospital
-
Fuzhou, 중국, 350005
- The First Affiliated Hospital of Fujian Medical University
-
Guangzhou, 중국, 510655
- The Sixth Affiliated Hospital of Sun Yat-sen University
-
Guangzhou, 중국, 510055
- Guangdong Provincial People's Hospital
-
Haikou, 중국, 570311
- Hainan General Hospital
-
Hangzhou, 중국, 310016
- Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
-
Hangzhou, 중국, 310022
- Zhejiang Cancer Hospital
-
Hangzhou, 중국, 310003
- The First Affiliated Hospital, College of Medicine, Zhejiang University
-
Hangzhou, 중국, 310017
- Second Affiliated Hospital of Zhejiang University School of Medicine
-
Harbin, 중국, 150081
- Harbin Medical University Cancer Hospital
-
Hefei, 중국, 230601
- The Second Affiliated Hospital of Anhui Medical University
-
Hefei, 중국, 230031
- Anhui Provincial Cancer Hospital
-
Hohhot, 중국, 01000
- Affiliated Hospital of Inner Mongolia Medical University
-
Jinan, 중국, 250013
- Jinan Central Hospital
-
Jinan, 중국, 250000
- Shandong Cancer Hospital
-
Kunming, 중국, 650118
- Yunnan Cancer Hospital
-
Lanzhou, 중국, 730050
- Gansu Cancer Hospital
-
Lanzhou, 중국, 730013
- The First Hospital of Lanzhou University
-
Nanchang, 중국, 330052
- The First Affiliated Hospital of Nanchang University
-
Nanjing, 중국, 210008
- Nanjing Drum Tower Hospital ,The Affiliated Hospital of Nanjing University Medical School
-
Qingdao, 중국, 266003
- The Affiliated Hospital of Qingdao University
-
Shanghai, 중국, 200032
- Fudan University Shanghai Cancer Center
-
Shanghai, 중국, 200080
- Shanghai General Hospital
-
Shanghai, 중국, 200032
- Fudan University Affiliated Zhongshan Hospital
-
Shanghai, 중국, 200025
- Ruijin hospital Shanghai Jiao Tong University School of Medicine
-
Shenyang, 중국, 110801
- Liaoning Cancer Hospital & Institute
-
Shijiazhuang, 중국, 50011
- The Fourth Hospital of Hebei Medical University
-
Tianjin, 중국, 300060
- Tianjin Medical University Cancer Institute & Hospital
-
Tianjin, 중국, 300041
- Tianjin Medical University General Hospital
-
Tonghua, 중국, 143099
- The Tonghua Central Hospital
-
Weihai, 중국, 264200
- Weihai Municipal Hospital
-
Wenzhou, 중국, 325000
- The First Affiliated Hospital of Wenzhou Medical University
-
Wuhan, 중국, 430079
- Hubei Cancer Hospital
-
Wuhan, 중국, 430023
- Union Hospital Tongji Medical College HuaZhong University of Science and Technology
-
Wuxi, 중국, 214062
- Affiliated Hospital of Jiangnan University
-
Xi'an, 중국, 710061
- First Affiliated Hospital of Xi 'an Jiaotong University
-
Xiamen, 중국, 361003
- The First Affiliated Hospital of Xiamen University
-
Yangzhou, 중국, 225001
- Northern Jiangsu People's Hospital
-
Zhengzhou, 중국, 450052
- The First Affiliated Hospital of Zhengzhou University
-
Zhengzhou, 중국, 450003
- Henan Cancer Hospital
-
Ürümqi, 중국, 830026
- Cancer Hospital affiliated to Xinjiang Medical University
-
-
-
-
-
Providencia, 칠레, 7500000
- Centro de Estudios Clínicos SAGA SpA
-
Santiago, 칠레, 7500000
- Sociedad Oncovida S.A
-
Santiago, 칠레, 8150513
- Icegclinic
-
Santiago, 칠레, 8330336
- BIOCINETIC SpA
-
Temuco, 칠레, 4810469
- Sociedad de Investigaciones Medicas Limitada
-
-
Region Metropolitan
-
Santiago, Region Metropolitan, 칠레, 8420383
- Centro Internacional de Estudios Clinicos CIEC
-
-
Santiago Metropolitan
-
Providencia, Santiago Metropolitan, 칠레, 7500000
- Fundación Arturo López Pérez (FALP) - PPDS
-
-
-
-
-
Toronto, 캐나다, M5G 2C1
- Princess Margaret Cancer Centre
-
-
-
-
-
Hat Yai, 태국, 90110
- Songklanagarind Hospital
-
Khon Kaen, 태국, 40000
- Srinagarind Hospital, Khon Kaen University
-
Lak Si, 태국, 10210
- Chulaborn Hospital
-
-
-
-
-
Ankara, 터키 (Türkiye), 06230
- Hacettepe Universitesi Kanser Enstitusu
-
Edirne, 터키 (Türkiye), 22030
- Trakya University Medical Faculty
-
Izmir, 터키 (Türkiye), 35220
- Dokuz Eylul Universitesi
-
Seyhan, 터키 (Türkiye), 01130
- Acibadem Adana Hospital
-
Trabzon, 터키 (Türkiye), 61310
- Medical Park Trabzon Yildizli
-
Yenimahalle, 터키 (Türkiye), 06200
- Dr. Abdurrahman Yurtaslan Ankara Onkology Training and Research Hospital
-
-
-
-
-
Almada, 포르투갈, 2801-951
- Hospital Garcia de Orta
-
Coimbra, 포르투갈, 3000-459
- Centro Hospitalar E Universitário de Coimbra EPE
-
Guimarães, 포르투갈, 4830-044
- Hospital Senhora da Oliveira - Guimaraes, E.P.E
-
Lisbon, 포르투갈, 1649-035
- Centro Hospitalar Lisboa Norte, E.P.E. - Hospital de Santa Maria
-
Matosinhos Municipality, 포르투갈, 4454-509
- Unidade Local de Saúde de Matosinhos SA
-
Porto, 포르투갈, 4200-072
- Instituto Portugues de Oncologia Do Porto Francisco Gentil Epe - PPDS
-
Porto, 포르투갈, 4099-001
- Centro Hospitalar do Porto EPE
-
-
-
-
-
Lodz, 폴란드, 93-513
- Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi
-
Warsaw, 폴란드, 02-034
- Centrum Onkologii Instytut im. Marii Sklodowskiej-Curie
-
-
-
-
-
Avignon, 프랑스, 84000
- Sainte-Catherine, Institut du Cancer Avignon Provence
-
Bordeaux, 프랑스, 33000
- EDOG - Institut Bergonie - PPDS
-
Dijon, 프랑스, 21079
- Universite de Bourgogne - Faculte de Medecine - IN
-
Grenoble, 프랑스, 38043
- Centre Hospitalier Universitaire Grenoble Alpes - Hopital Albert Michallon
-
Lyon, 프랑스, 69008
- Centre Léon Berard
-
Nantes, 프랑스, 44805
- EDOG Institut de Cancerologie de l'Ouest - PPDS
-
Poitiers, 프랑스, 86021
- CHRU de Poitiers La Miletrie
-
Rennes, 프랑스, 35000
- EDOG - Centre Eugene Marquis Centre Regional de Lutte Contre Le Cancer - PPDS
-
Saint-Priest-en-Jarez, 프랑스, 42270
- CHRU de Brest - Hopital Morvan
-
Toulouse, 프랑스, 69437
- Hôpital de Rangueil
-
Villejuif, 프랑스, 94800
- Hôpital Saint Antoine
-
-
Gironde
-
Pessac, Gironde, 프랑스, 33600
- CHU de Bordeaux - Hopital Haut Leveque
-
-
-
-
-
Bedford Park, 호주, 5042
- Flinders Medical Centre
-
Heidelberg, 호주, 3084
- Austin Health
-
Liverpool, 호주, 2170
- Liverpool Hospital
-
Murdoch, 호주, 6150
- Fiona Stanley Hospital
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Histologically confirmed unresectable locally advanced, recurrent or metastatic HER2-positive gastroesophageal adenocarcinoma (adenocarcinomas of the stomach or esophagus, including the gastroesophageal junction), defined as 3+ HER2 expression by IHC or 2+ HER2 expression by IHC with ISH positivity per central assessment. Subjects with esophageal adenocarcinoma must not be eligible for combined chemoradiotherapy at the time of enrollment
- Assessable (measurable or non-measurable) disease as defined by RECIST 1.1
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1, assessed within 3 days prior to randomization
- Adequate organ function
- Left ventricular ejection fraction (LVEF) ≥ 50% as determined by either echocardiogram or multiple gated acquisition scan (MUGA)
Exclusion Criteria:
- Prior treatment with a HER2-targeted agent, with the exception of subjects who received HER2-targeted treatment for breast cancer > 5 years prior to initial diagnosis of GEA
- Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2 or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
- Prior treatment with systemic antineoplastic therapy or intraperitoneal chemotherapy for unresectable locally advanced, recurrent or metastatic GEA
- Untreated central nervous system (CNS) metastases, symptomatic CNS metastases, or radiation treatment for CNS metastases within 4 weeks prior to randomization. Stable, treated brain metastases are allowed (defined as subjects who are completely off steroids and anticonvulsants and are neurologically stable with no evidence of radiographic progression for at least 4 weeks prior to randomization)
- Known history of or ongoing leptomeningeal disease (LMD)
- Known additional malignancy that is not considered cured or that has required treatment within the past 3 years
- Known active hepatitis
- Any history of human immunodeficiency virus (HIV) infection
- Known SARS-CoV-2 infection; subjects with prior infection that has resolved per local institutions' requirements and screening guidance are eligible
- QTc Fridericia (QTcF) > 470 ms
- Clinically significant cardiac disease, such as ventricular arrhythmia requiring therapy, uncontrolled hypertension or any history of symptomatic congestive heart failure (CHF)
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
활성 비교기: Arm A
Trastuzumab (Herceptin®) plus physician's choice of capecitabine plus oxaliplatin (CAPOX) or 5-fluorouracil (5-FU) plus cisplatin (FP) |
Administered intravenously (IV)
다른 이름들:
Administered orally (PO bid) Administered IV Administered IV Administered IV |
|
실험적: Arm B
Zanidatamab plus physician's choice of CAPOX or FP |
Administered orally (PO bid) Administered IV Administered IV Administered IV Administered IV
다른 이름들:
|
|
실험적: Arm C
Zanidatamab and tislelizumab plus physician's choice of CAPOX or FP |
Administered orally (PO bid) Administered IV Administered IV Administered IV Administered IV
다른 이름들:
Administered IV |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Progression-free survival (PFS) by BICR
기간: Up to 2.5 years
|
The time from randomization to the date of documented disease progression (per Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1) as assessed by blinded independent central review (BICR) or death from any cause |
Up to 2.5 years
|
|
Overall survival
기간: Up to 3.5 years
|
The time from randomization to death due to any cause |
Up to 3.5 years
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Zanidatamab 및 tislelizumab의 혈청 농도
기간: 최대 2년
|
최대 2년
|
|
|
Confirmed objective response rate (ORR) by BICR
기간: Up to 2.5 years
|
Number of patients who achieved a best overall response of complete response (CR) or (PR) as determined per RECIST 1.1 as assessed by BICR |
Up to 2.5 years
|
|
Duration of response (DOR) by BICR
기간: Up to 2.5 years
|
The time from the first objective response (CR or PR) per BICR to documented progressive disease per RECIST 1.1 as assessed by BICR or death from any cause |
Up to 2.5 years
|
|
PFS per Investigator assessment
기간: Up to 2.5 years
|
The time from randomization to the date of documented disease progression (per RECIST 1.1) as assessed by Investigator or death from any cause |
Up to 2.5 years
|
|
Confirmed ORR per Investigator assessment
기간: Up to 2.5 years
|
Number of patients who achieved a best overall response of CR or PR as determined per RECIST 1.1 as assessed by Investigator |
Up to 2.5 years
|
|
DOR per Investigator assessment
기간: Up to 2.5 years
|
The time from the first objective response (CR or PR) per Investigator to documented progressive disease per RECIST 1.1 as assessed by Investigator or death from any cause |
Up to 2.5 years
|
|
Assessment of Contribution of Components based on Progression-free Survival (PFS) by BICR
기간: Up to 2.5 years
|
The time from randomization to the date of documented disease progression (per Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1) as assessed by blinded independent central review (BICR) or death from any cause |
Up to 2.5 years
|
|
Assessment of Contribution of Components based on Overall Survival
기간: Up to 3.5 years
|
The time from randomization to death due to any cause |
Up to 3.5 years
|
|
Incidence of adverse events
기간: Up to 2 years
|
Number of subjects who experienced adverse events or serious adverse events |
Up to 2 years
|
|
Incidence of clinical laboratory abnormalities
기간: Up to 2 years
|
Number of patients who experienced a maximum severity of Grade 3 or higher post-baseline laboratory abnormality, including either hematology or chemistry. Grades are defined using National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE), version 5.0 |
Up to 2 years
|
|
Health-related quality of life (HRQoL) as assessed by the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (core cancer questionnaire) C30 (QLQ-C30)
기간: Up to 2.5 years
|
Changes from baseline in the EORTC QLQ-C30 scores |
Up to 2.5 years
|
|
HRQoL as assessed by the EORTC Quality of Life Questionnaire (oesophago-gastric module) OG25 (QLQ-OG25)
기간: Up to 2.5 years
|
Changes from baseline in the EORTC QLQ-OG25 scores |
Up to 2.5 years
|
|
HRQoL as assessed by the EuroQol 5-dimensions 5-levels (EQ-5D-5L) questionnaire
기간: Up to 2.5 years
|
Changes from baseline in the EORTC EQ-5D-5L questionnaire scores |
Up to 2.5 years
|
|
Incidence of anti-drug antibodies (ADAs)
기간: Up to 2 years
|
Number of patients who develop ADAs |
Up to 2 years
|
공동 작업자 및 조사자
협력자
협력자
간행물 및 유용한 링크
일반 간행물
- Tabernero J, Shen L, Elimova E, Ku G, Liu T, Shitara K, Lin X, Boyken L, Li H, Grim J, Ajani J. HERIZON-GEA-01: Zanidatamab + chemo +/- tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma. Future Oncol. 2022 Sep;18(29):3255-3266. doi: 10.2217/fon-2022-0595. Epub 2022 Aug 24.
- Lee KW, Bai LY, Jung M, Ying J, Im YH, Oh DY, Cho JY, Oh SC, Chao Y, Kim JW, Chen Y, Li V, Chen S, Kang YK. Phase Ib/II Study of Zanidatamab in Combination with Tislelizumab and Chemotherapy in First-Line HER2-Positive Gastric/Gastroesophageal Junction Adenocarcinoma. Clin Cancer Res. 2026 Jan 16;32(2):312-323. doi: 10.1158/1078-0432.CCR-24-4295.
- Yu J, Mehta R. Biomarker-Driven Approach to the Treatment of Metastatic Gastric or Gastroesophageal Adenocarcinoma. J Natl Compr Canc Netw. 2025 May;23(5):e257036. doi: 10.6004/jnccn.2025.7036.
- Shitara K, Elimova E, Liu T, Tabernero J, Lee KW, Schenker M, Tebbutt NC, Ajani J, Salimin N, Ku G, Gwang Kim J, Ales Diaz I, Zhang J, Pietrantonio F, Bai LY, Le Sourd S, Zhao J, Hierro C, Kiberu A, Van Herpe F, Bao Y, Zhang H, Yang L, Li V, Gartner EM, Chen Y, Grim J, Rha SY, Shen L; HERIZON-GEA-01 Investigators. Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer. N Engl J Med. 2026 May 28;394(20):2002-2014. doi: 10.1056/NEJMoa2517729.
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (실제)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
- 부위별 신생물
- 신생물
- 위장관 신생물
- 소화계 신생물
- 소화기계 질환
- 위장병
- 위장병
- 두경부 신생물
- 식도 질환
- 위 신생물
- 식도 신생물
- 파킨슨 병 4, 상 염색체 우성 루이 바디
- 식도 선암종
- 아미노산, 펩티드 및 단백질
- 단백질
- 유기 화학 물질
- 이종 사이 클릭 화합물, 1- 링
- 이종 사이 클릭 화합물
- 핵산, 뉴클레오티드 및 뉴 클레오 시드
- 항체, 모노클로 날, 인간화
- 항체, 모노클로 날
- 항체
- 면역 글로불린
- 면역 단백질
- 혈액 단백질
- 혈청 글로불린
- 글로불린
- 무기 화학 물질
- 염소 화합물
- 질소 화합물
- 조정 복합체
- 데 옥시 시티 딘
- 시티 딘
- 피리 미딘 뉴 클레오 시드
- 피리 미딘
- 뉴 클레오 시드
- 우라실
- 피리 미디 논
- 백금 화합물
- 데 옥시 리보 뉴 클레오 시드
- 트라스투주맙
- 카페시타빈
- 옥살리플라틴
- 플루오로우라실
- 시스플라틴
- 자니 다타 맙
- Tislelizumab
기타 연구 ID 번호
기타 연구 ID 번호
- ZWI-ZW25-301
- 2021-000296-36 (EudraCT 번호)
- jRCT2061230026 (레지스트리 식별자: Japan Registry for Clinical Trials (jRCT))
- 2023-510319-20-00 (씨티스)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
In accordance with ICMJE requirements, Jazz Pharmaceuticals may provide qualified external researchers access to individual participant data (IPD) and clinical trial data that underlie the results of this trial upon request. Qualified researchers can submit a request on https://www.jazzpharma.com/science/clinical-trial-data-sharing/ as outlined. Jazz Pharmaceuticals reserves the right not to consider a request. For inquiries about Jazz's data sharing policy contact clinicaldatasharing@jazzpharma.com.
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .